vancomycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, produced by Streptomyces strains	2807	1404-90-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: vancomycin diatracin vancocin vancocine vancoled vancomycin hydrochloride vancomycin HCl	Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. Molecular weight: 1449.27 Formula: C66H75Cl2N9O24 CLOGP: -2.23 LIPINSKI: 3 HAC: 33 HDO: 19 TPSA: 530.49 ALOGS: -3.81 ROTB: 13

Molecule

Description

Molfile Inchi Smiles

Synonyms:

vancomycin
diatracin
vancocin
vancocine
vancoled
vancomycin hydrochloride
vancomycin HCl

Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.

Molecular weight: 1449.27
Formula: C66H75Cl2N9O24
CLOGP: -2.23
LIPINSKI: 3
HAC: 33
HDO: 19
TPSA: 530.49
ALOGS: -3.81
ROTB: 13

Drug dosage:

Dose	Unit	Route
2	g	O
2	g	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
EoM (Fraction excreted unchanged in urine)	79 %	Benet LZ, Broccatelli F, Oprea TI
t_half (Half-life)	6.50 hours	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	5 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	22.44 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
S (Water solubility)	100 mg/mL	Bocci G, Oprea TI, Benet LZ
CL (Clearance)	1.30 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.70 %	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.54 L/kg	Lombardo F, Berellini G, Obach RS

Showing 1 to 9 of 9 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Nov. 6, 1964	FDA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	1978.59	11.72	913	74936	32923	63380250
Acute kidney injury	1529.22	11.72	1720	74129	261695	63151478
Linear IgA disease	746.88	11.72	199	75650	1252	63411921
Multiple organ dysfunction syndrome	700.25	11.72	564	75285	56188	63356985
Septic shock	540.59	11.72	522	75327	66107	63347066
Renal tubular necrosis	528.24	11.72	266	75583	11612	63401561
Eosinophilia	514.11	11.72	327	75522	22429	63390744
Acute generalised exanthematous pustulosis	454.18	11.72	235	75614	10864	63402309
Toxic epidermal necrolysis	423.48	11.72	302	75547	25032	63388141
Nephropathy toxic	400.26	11.72	205	75644	9274	63403899

Showing 1 to 10 of 608 entries

Previous1 2 3 4 5…61Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	2091.63	11.73	1188	84509	31824	34839410
Acute kidney injury	1128.65	11.73	2371	83326	302617	34568617
Linear IgA disease	1066.02	11.73	315	85382	1311	34869923
Renal tubular necrosis	564.45	11.73	395	85302	15285	34855949
Multiple organ dysfunction syndrome	466.00	11.73	741	84956	75825	34795409
Eosinophilia	427.71	11.73	417	85280	25805	34845429
Rash maculo-papular	395.55	11.73	415	85282	28036	34843198
Septic shock	384.16	11.73	656	85041	71178	34800056
Toxic epidermal necrolysis	371.41	11.73	354	85343	21292	34849942
Fatigue	366.76	11.73	229	85468	370424	34500810

Showing 1 to 10 of 577 entries

Previous1 2 3 4 5…58Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	3907.40	11.18	2039	144012	62205	79536132
Acute kidney injury	2558.32	11.18	3882	142169	515522	79082815
Linear IgA disease	1771.82	11.18	507	145544	2625	79595712
Renal tubular necrosis	1112.57	11.18	647	145404	24392	79573945
Multiple organ dysfunction syndrome	1015.73	11.18	1175	144876	119071	79479266
Eosinophilia	936.87	11.18	728	145323	44617	79553720
Septic shock	846.69	11.18	1083	144968	121718	79476619
Nephropathy toxic	692.52	11.18	444	145607	19975	79578362
Fatigue	690.76	11.18	427	145624	929300	78669037
Toxic epidermal necrolysis	679.27	11.18	600	145451	43981	79554356

Showing 1 to 10 of 886 entries

Previous1 2 3 4 5…89Next

FDA Adverse Event Reporting System (Pediatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	50.52	26.56	41	401	1011	88339
Foetal exposure during pregnancy	49.78	26.56	5	437	12836	76514
Systemic candida	32.55	26.56	11	431	33	89317

Showing 1 to 3 of 3 entries

Previous1Next

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	A07AA09	ALIMENTARY TRACT AND METABOLISM ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS INTESTINAL ANTIINFECTIVES Antibiotics
ATC	J01XA01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER ANTIBACTERIALS Glycopeptide antibacterials
ATC	S01AA28	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Antibiotics
CHEBI has role	CHEBI:33281	antibiotics
CHEBI has role	CHEBI:36047	antibacterial drugs
FDA CS	M0009481	Glycopeptides
FDA EPC	N0000175491	Glycopeptide Antibacterial
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Showing 1 to 9 of 9 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Bacterial septicemia	indication	10001005	DOID:0040085
Staphylococcal pneumonia	indication	22754005
Staphylococcal enterocolitis	indication	32527003
Lower respiratory tract infection	indication	50417007
Staphylococcal infectious disease	indication	56038003
Staphylococcal endocarditis	indication	73028002
Infection of bone	indication	111253001
Staphylococcal septicemia	indication	111821004
Sepsis of the newborn	indication	206376005
Neonatal pneumonia	indication	233619008

Showing 1 to 10 of 43 entries

Previous1 2 3 4 5Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Show entries

Search:

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.55	acidic
pKa10	13.2	acidic
pKa11	13.59	acidic
pKa12	8.96	Basic
pKa13	8.3	Basic
pKa2	7.69	acidic
pKa3	10.72	acidic
pKa4	11.48	acidic
pKa5	11.49	acidic
pKa6	12.17	acidic

Showing 1 to 10 of 13 entries

Previous1 2Next

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
5GM/100ML (50MG/ML)	VANCOMYCIN	XELLIA PHARMS APS	N213895	Aug. 26, 2021	RX	SOLUTION	INTRAVENOUS, ORAL	10039804	Nov. 6, 2035	METHOD OF TREATING BACTERIAL INFECTIONS
5GM/100ML (50MG/ML)	VANCOMYCIN	XELLIA PHARMS APS	N213895	Aug. 26, 2021	RX	SOLUTION	INTRAVENOUS, ORAL	10188697	Nov. 6, 2035	METHOD OF TREATING BACTERIAL INFECTIONS
5GM/100ML (50MG/ML)	VANCOMYCIN	XELLIA PHARMS APS	N213895	Aug. 26, 2021	RX	SOLUTION	INTRAVENOUS, ORAL	11517609	Nov. 6, 2035	METHOD OF TREATING BACTERIAL INFECTIONS
EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	VANCOMYCIN HYDROCHLORIDE	XELLIA PHARMS APS	N211962	May 13, 2020	RX	SOLUTION	INTRAVENOUS	10039804	Nov. 6, 2035	METHOD OF TREATING BACTERIAL INFECTIONS
EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	VANCOMYCIN HYDROCHLORIDE	XELLIA PHARMS APS	N211962	May 13, 2020	RX	SOLUTION	INTRAVENOUS	10188697	Nov. 6, 2035	METHOD OF TREATING BACTERIAL INFECTIONS
EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	VANCOMYCIN HYDROCHLORIDE	XELLIA PHARMS APS	N211962	May 13, 2020	RX	SOLUTION	INTRAVENOUS	11517609	Nov. 6, 2035	METHOD OF TREATING BACTERIAL INFECTIONS
EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	VANCOMYCIN HYDROCHLORIDE	XELLIA PHARMS APS	N211962	Feb. 15, 2019	RX	SOLUTION	INTRAVENOUS	10039804	Nov. 6, 2035	METHOD OF TREATING BACTERIAL INFECTIONS
EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	VANCOMYCIN HYDROCHLORIDE	XELLIA PHARMS APS	N211962	Feb. 15, 2019	RX	SOLUTION	INTRAVENOUS	10188697	Nov. 6, 2035	METHOD OF TREATING BACTERIAL INFECTIONS
EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	VANCOMYCIN HYDROCHLORIDE	XELLIA PHARMS APS	N211962	Feb. 15, 2019	RX	SOLUTION	INTRAVENOUS	11517609	Nov. 6, 2035	METHOD OF TREATING BACTERIAL INFECTIONS
EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML)	VANCOMYCIN HYDROCHLORIDE	XELLIA PHARMS APS	N211962	May 13, 2020	RX	SOLUTION	INTRAVENOUS	10039804	Nov. 6, 2035	METHOD OF TREATING BACTERIAL INFECTIONS

Showing 1 to 10 of 36 entries

Previous1 2 3 4Next

Orange Book exclusivity data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 250MG BASE/5ML	VANCOMYCIN HYDROCHLORIDE	AMNEAL	A215338	June 23, 2023	RX	FOR SOLUTION	ORAL	Dec. 20, 2023	COMPETITIVE GENERIC THERAPY

Showing 1 to 1 of 1 entries

Previous1Next

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN	Ki	7.30	CHEMBL
D-alanyl-D-alanine dipeptidase	Enzyme		VANX_ENTFC	Ki	4.21	CHEMBL
UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase	Enzyme		MURG_ECOLI	IC50	5	CHEMBL

Showing 1 to 3 of 3 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
002791	NDDF
004866	NDDF
10932	IUPHAR_LIGAND_ID
11124	RXNORM
1404-93-9	SECONDARY_CAS_RN
14969	PUBCHEM_CID
253520	MMSL
30222	MMSL
3125	MMSL
372735009	SNOMEDCT_US

Showing 1 to 10 of 31 entries

Previous1 2 3 4Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
VANCOMYCIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0867	CAPSULE	125 mg	ORAL	ANDA	26 sections
VANCOMYCIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0867	CAPSULE	125 mg	ORAL	ANDA	26 sections
VANCOMYCIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0867	CAPSULE	125 mg	ORAL	ANDA	26 sections
VANCOMYCIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0867	CAPSULE	125 mg	ORAL	ANDA	26 sections
VANCOMYCIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0890	CAPSULE	250 mg	ORAL	ANDA	26 sections
VANCOMYCIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0890	CAPSULE	250 mg	ORAL	ANDA	26 sections
VANCOMYCIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0890	CAPSULE	250 mg	ORAL	ANDA	26 sections
VANCOMYCIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0890	CAPSULE	250 mg	ORAL	ANDA	26 sections
Vancomycin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9152	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1.25 g	INTRAVENOUS	ANDA	29 sections
Vancomycin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9153	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1.50 g	INTRAVENOUS	ANDA	29 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next